TG4050
TG4050 is an individualized therapeutic vaccine
A particularly innovative immunotherapy, TG4050 is the lead myvac ® candidate.
Clinical Proof of Principle
in head and neck cancer
All treated patients remain disease-free after a median follow up of 24.1 months
One cancer, one patient, one vaccine
With TG4050, Transgene is developing an individualized immunotherapy based on advanced genetic engineering and artificial intelligence (AI) technologies.
The treatment is based on an optimized MVA viral vector.
myvac® video Each treatment is designed and manufactured by Transgene for each patient, targeting the most relevant tumor targets (cancer-specific neoantigens) selected by NEC’s AI.
Once injected into the patient, this therapeutic vaccine will stimulate the patient’s immune defenses to allow the targeted destruction of cancer cells.
To carry out this project, Transgene relies on a unique expertise, a network of prestigious and recognized partners at every stage of product development and integrated manufacturing capabilities.
Collaboration agreements
Transgene has signed a strategic collaboration agreement with NEC for the development of TG4050, the first candidate derived from the myvac® platform. This personalized immunotherapy is developed for each patient, on the basis of mutations identified through sequencing of tumor tissue, prioritized using NEC’s Neoantigen Prediction System and delivered using Transgene’s myvac® technological platform which allows development and manufacturing.
Clinical trials
| Indication | Phase | |
|---|---|---|
| HPV-negative head and neck cancers – after surgery and adjuvant therapy | Phase I/II | More information |
- November 7, 2024 - Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
- October 7, 2024 - Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
- June 3, 2024 - Transgene – First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
- Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)
C. Le Tourneau, et al.
SITC 2024
Abstract available on the SITC website – Download the abstract and the poster
- Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers
A. Lalanne, et al.
AACR 2024
Abstract available on the AACR website – Download the poster
Poster Presentation - Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma
C. Ottensmeier, et al.
ASCO 2023
Abstract available on the ASCO website – Download the abstract and the poster
Poster Presentation
